ImmuPharma plc (LON:IMM – Get Free Report) shares fell 8.3% on Wednesday . The company traded as low as GBX 4.11 ($0.05) and last traded at GBX 4.59 ($0.06). 7,864,863 shares were traded during trading, a decline of 65% from the average session volume of 22,321,723 shares. The stock had previously closed at GBX 5 ($0.06).
ImmuPharma Price Performance
The company has a market cap of £19.10 million, a P/E ratio of -458.70 and a beta of 1.53. The stock’s 50-day moving average price is GBX 2.28 and its 200-day moving average price is GBX 1.89.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- What is Put Option Volume?
- 3 Must-Have ETFs Set to Dominate This Quarter
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Seeking Stability? These 3 Stocks Offer Strong Potential
- What Are Growth Stocks and Investing in Them
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
